To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Arbidol (Russian: Арбидол) is an antiviral drug manufactured by Masterlek in Moscow, Russia. It is an alternative to Tamiflu (manufactured by Roche Pharmaceuticals) used in the fight against avian influenza. Its antiviral inhibitory effect is still being tested and the current results range from being well accepted in pharmaceutical industry to accepted with a dose of suspicion.
Chemically, Arbidol features an indole core, functionalized at all positions but one with different substituents. The drug has mainly been tested in Russia and China, and has been shown to be effective against avian flu, suggesting it might be a more affordable and cost-effective drug than the widely used Tamiflu.
Mechanism of action
According to the manufacturer, the drug exhibits immunomodulation as well as a specific anti-influenza action against the influenza A and influenza B viruses. It prevents contact between the virus and host cells and penetration of virus particles into the cell by inhibiting the fusion of the virus lipid shell to the cell membranes. It possesses interferon inducing action, by stimulating the humoral reaction and the phagocytic function of macrophages.
Pharmacokinetics and usage
An orally administered dose of 50 mg reaches its maximum concentration in the blood in about 1 h, and a dose of 100 mg reaches its maximum concentration within 1.5 h. It is metabolized in the liver. The period of half-life is about 17-21 h. Both the tablet and capsule forms should be taken before a meal. Dosage for children of ages 2-6 is 50 mg daily, for 6-12 years of age 100 mg daily, and 12 years and older should take 200 mg daily. Side effects in children include sensitization to the drug. No known overdose cases have been reported and allergic reactions are limited to people with hypersensitivity.
|HIV (Reverse, VI)||See HIV pharm|
|Other antiviral agents||general (Inosine, Interferon)|
|†Undergoing clinical trials, not FDA approved.|